A double-blind, placebo-controlled, four-arm, single-dose, cross over, dose-ranging trial to investigate the effects of Reducose mulberry leaf extract on postprandial glucose and insulin after consuming a complex meal

Phynova Group Ltd0 个研究点目标入组 43 人开始时间: 2022年6月8日最近更新: 2024年7月29日

适应症

试验速览

2024 Results article in https://doi.org/10.3390/nu16111670 (added 19/07/2024)

•1. Aged< 18 or> 60 years
•2. Pregnant or lactating
•3. Body mass index (BMI) <18.5 or >30 kg/m²
•4. Fasting blood glucose value >6.1 mmol/I
•5. Any known food allergy or intolerance
•6. Medical condition(s) or medication(s) known to affect glucose regulation or appetite and/or which influence digestion and absorption of nutrients (stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable)
•7. Known history of diabetes mellitus or the use of antihyperglycaemic drugs or insulin to treat diabetes and related conditions
•8. Known IBS, severe liver, heart or kidney problems or blood clotting disorders
•9. Major medical or surgical event requiring hospitalization within the preceding 3 months
•10. Use of steroids, protease inhibitors or antipsychotics (all of which have major effects on glucose metabolism and body fat distribution)
•11. High vulnerability level for COVID-19 (assessed using this tool - https://alama.org.uk/covid- 19-medical-risk-assessment/)
•12. Displayed any COVID-19 symptoms 14 days prior to any test session (high temperature, new continuous cough, loss or change to sense of smell or taste)

发起方